Single-dose adenovirus vaccines against multiple new coronavirus mutations such as Delta show neutralizing activity

Recently, Johnson & Johnson announced that the latest research results show that its single-dose new crown vaccine Ad26.

Ad26.

In the preprint study submitted by Johnson & Johnson, the researchers evaluated the neutralizing ability of the serum of eight volunteers who participated in the phase 3 clinical trial

The researchers used lentiviral vectors to express the spike proteins of different new crown mutants, and used pseudovirus neutralization tests to measure the neutralization ability of the serum

The test results showed that compared with the B.

▲Neutralizing titers of volunteer serum against different new coronavirus mutants after a dose of Ad26.

The researchers stated in the paper that this study showed that the serum neutralization activity of Ad26.

Johnson & Johnson’s press release pointed out that in another study submitted to bioRxiv by Dr.

Moreover, the level of neutralizing antibodies against multiple mutant viruses listed by the World Health Organization increased over time after vaccination

Reference materials:

[1] Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response.

[2] Jongeneelen et al.